Compugen Ltd. is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy. The company utilizes Unigen, an AI and machine learning-powered computational discovery platform, to identify novel drug targets and develop therapeutics. Its clinical pipeline includes COM701, a potential first-in-class anti-PVRIG antibody, and COM902, a high-affinity anti-TIGIT antibody. Rilvegostomig, a PD-1/TIGIT bispecific antibody derived from the COM902 program, is being developed by AstraZeneca under an exclusive license agreement. GS-0321, a high-affinity antibody blocking the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is currently in Phase 1 clinical trials. The company also maintains an early-stage immuno-oncology research pipeline. Compugen was incorporated in 1993 and operates through its wholly owned U.S. subsidiary, Compugen USA, Inc.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage cgen.com
Sector Healthcare IR page cgen.com/investors-and-media/overview/default.aspx
Tags
cancer immunotherapy, computational drug discovery, antibody therapeutics, immune checkpoint inhibitors, bispecific antibodies, ai drug discovery, oncology, target discovery, Unigen, COM701, COM902, rilvegostomig, GS-0321, COM503, Compugen USA Inc.
Press page —

Metrics

Valuation  
Market cap $ 225.443M
Market cap (USD) $ 225.443M
P/E 6.26
PEG —
P/BV 2.54
P/S 3.10
P/OCF 7.13
P/FCF 7.20
Dividend yield —
Turnover / mcap —
Returns  
ROE 44.8%
ROI 242.5%
ROIC 214.6%
Profit margin 48.6%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 72.764M 27.864M 33.459M 7.5M 6M 2M — 17.8M — 712K 9.277M 12.367M 3.549M 242K — 1.115M 250K
Net profit 35.343M -14.231M -18.754M -33.694M -34.203M -29.698M -27.337M -22.599M -37.066M -31.506M -20.163M -11.094M -14.083M -13.628M -12.004M -7.203M -3.831M
Free cash flow 31.328M 49.486M -36.058M -34.983M -23.042M -28.486M -28.043M -13.449M -31.043M -22.418M -28.727M -13.044M -6.767M -11.851M -9.345M -4.325M -7.501M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 1.53 1.53 1.98 0.72 4.3 12.11 5.96 2.17 2.5 5.1 6.39 8.33 8.95 — — 8.28 —
Price performance 12m 0 -0.23 1.77 -0.83 -0.64 1.03 1.75 -0.13 -0.51 -0.2 -0.23 -0.07 — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 2M — 0.00 61M 0.00 —
↳ YoY growth -100.0%
↳ 5y CAGR -23.8%
Lease liabilities (USD) — — — 3.58M 3.17M 2.75M 1.93M 1.35M 2.91M 2.96M
Cash and deposits (USD) 9.71M 25.5M 5.86M 9.19M 7.14M 7.8M 11.1M 13.9M 18.2M 90.6M
Right-of-use assets (USD) — — — 3.25M 2.77M 2.25M 1.83M 1.33M 2.84M 2.52M
Cash flow detail
Operating cash flow (USD) -19.8M -30.7M -13.3M -27.9M -28.3M -22.8M -34.5M -35.9M 49.6M 31.6M
Purchases of property, plant and equipment (USD) -2.6M -385,000 -158,000 -155,000 -166,000 -292,000 -477,000 -172,000 -118,000 -306,000
Change in receivables (cash effect) (USD) 7.8M 422,000 -179,000 -142,000 -1.61M -2.8M 3.04M -112,000 -213,000 360,000
Change in payables (cash effect) (USD) -605,000 1.56M 4.09M -3.5M 3.82M 3.37M -1.6M 3.51M -4.41M —
Interest paid (cash effect) (USD) -1.03M — — — — — — — — —
Income taxes paid (cash effect) (USD) -20,000 — — — — — — -12,000 -13.5M -55,000
Share-based compensation (USD) 3.08M 2.63M 2.17M 2.41M 2.77M 4.28M 4.33M 3.55M 3.02M 1.88M
Operating cash flow before change in receivables (USD) -27.6M -31.1M -13.1M -27.7M -26.7M -19.9M -37.5M -35.8M 49.8M 31.3M
Free cash flow (OCF - PPE - intangibles) (USD) -22.4M -31M -13.4M -28M -28.5M -23M -35M -36.1M 49.5M 31.3M
Income detail
Research and development expense (USD) 24.5M 28.6M 30.3M 19.8M 22.8M 28.7M 30.6M 34.5M 24.8M 22.8M
↳ 5y CAGR +29.4% +24.8% +19.8% +5.6% +1.4% +3.2% +1.4% +2.6% +4.6% >-0.01%
Total comprehensive income (USD) -31.9M -37.1M -22.6M -27.3M -29.7M -34.2M -33.7M -18.8M -14.2M 35.3M
Comprehensive income to owners (USD) -31.9M -37.1M -22.6M -27.3M -29.7M -34.2M -33.7M -18.8M -14.2M 35.3M
Reported Feb 16, 2017 Mar 21, 2019 Mar 21, 2019 Feb 24, 2020 Feb 25, 2021 Feb 28, 2022 Mar 5, 2024 Mar 2, 2026 Mar 2, 2026 Mar 2, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Compugen Reports Third Quarter 2026 Results Bull 2 Bear 0 Results

MAIA-ovarian fully enrolled; results expected by end of Q1 2027

Phase 3 rilvegostomig high-level results from partner AstraZeneca anticipated in H2 2027

from ARTEMIDE-Biliary01 trial

UnigenX™ designed to expand AI-powered discovery engine into tumor-associated antigens for

targeted immune activation modalities

Cash runway expected into 2029

HOLON, Israel, November 9, 2026 /PRNewswire/ - Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today reported financial results for the third quarter of 2026 and provided a corporate update.

“During the third quarter, we continued to advance COM701 and GS-0321 in the clinic, as well as build the next generation of our pipeline,” said Eran Ophir, Ph.D., President and Chief Executive Officer of Compugen. “MAIA-ovarian is now fully enrolled, and we remain on track to report results by the end of the first quarter of 2027.We are also excited to see partner AstraZeneca continue to progress rilvegostomig, with Phase 3 high-level trial results from ARTEMIDE-Biliary01 anticipated in the second half of 2027.

November 3, 2026

HOLON, Israel, Nov. 3, 2026 /PRNewswire/ -- Compugen Ltd.  (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI, today announced that management will participate in the following upcoming investor conferences in November 2026:

**Stifel 2026 Healthcare Conference
**Date: Tuesday, November 10, 2026
Location: New York, NY
Format: Fireside chat and 1x1 meetings
Fireside chat time: 11:20 am ET

2026 Jefferies Global Healthcare Conference Date: Wednesday and Thursday, November 18-19, 2026
Location: London, UK
Format: 1x1 meetings

Please contact your Stifel or Jefferies representative for additional information or to schedule a meeting with Compugen.

A live webcast of the fireside chat will be available on the events page of the Investor Relations section of Compugen's website  at www.cgen.com . A replay will be available following the live event.

**About Compugen
**Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI-powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

**Company Contact:
**Lindsey Trickett
Head of Investor Relations and Corporate Communications
Email: [email protected]

Tel: +1 (628) 241-0071

Cision View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-november-investor-conferences-302927594.html

SOURCE Compugen Ltd.

View All News

Headquarters

Compugen Ltd.

Azrieli Center
26 Harokmim St., Bldg D
Holon 5885849, Israel

Investor Contact

Investor Relations
Telephone: +16282410071
Email: [email protected]

Investor Email Alerts

Personal Information.

Your Email *Required Email Address is required. Email Address is invalid.

Mailing Lists *

  • Press Releases
  • End of Day Stock Quote
  • Events

Investor Alert Options is required.

The captcha test has failed. Please try again.

Sign up

Unsubscribe

About

Unigen™

Pipeline

Clinical Trials

Visit Linkedin    Visit X (Formally Twitter)

© 2026 Compugen Ltd - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

Toggle toolbar

Accessibility Tools

October 26, 2026

HOLON, Israel, Oct. 26, 2026 /PRNewswire/ -- Compugen Ltd.

(NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI, today announced that the Company will release its third quarter 2026 financial results on Monday, November 9, 2026, before the U.S. financial markets open. That same day, management will host a conference call to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-9180644 internationally. The call will be available via live webcast through Compugen's website, which is located at the following link.

Following the live webcast, a replay will be available on the Company's website.

Prompts

Compugen Ltd. (ticker CGEN), listed in United States.

ETFs Holding Compugen Ltd.

ETF Weight in ETF Shares Market value As of
AVSD 0.01% 11,762 $ 23.994K Nov 16, 2026
AVDV 0.00% 87,369 $ 178.233K Nov 16, 2026